Garnet Health Among First in Hudson Valley to Offer Aquablation Therapy, a New Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia

MIDDLETOWN, NY (April 19, 2024) — Garnet Health is pleased to announce that it is the first health system in the Hudson Valley to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

This advanced, minimally invasive treatment uses the power of water delivered with robotic precision to provide long-lasting BPH relief without compromise. Aquablation therapy is performed by the AquaBeam® Robotic System, the first FDA-cleared surgical robot utilizing automated tissue resection for the treatment of LUTS due to BPH. Aquablation therapy combines real-time multidimensional imaging, automated robotics and heat-free water-jet ablation for targeted, controlled and immediate removal of prostate tissue. 

“We are proud to be among the first in the Hudson Valley to offer a solution for men with BPH that provides significant, long-lasting symptom relief, with lower risk to their sexual function or continence,” said Samuel Abourbih, MD, urologist with Garnet Health Doctors and Garnet Health Medical Center’s department chair of urology. “Aquablation therapy is another step to furthering our commitment to robotic surgery and men’s health.”

BPH, or an enlarged prostate, is a noncancerous condition where the prostate has grown to be larger than normal. Aquablation therapy is the only BPH surgical procedure that integrates ultrasound imaging with the standard camera (called a cystoscope). This gives Garnet Health surgeons the ability to see the entire prostate in real time, allowing them to map which parts of the prostate they want to remove and which parts they want to avoid.

Both Dr. Abourbih and Gerard Galarneau, MD, urologist with Garnet Health Doctors, are trained in aquablation therapy.

“Current BPH surgical treatments often force men to choose between symptom relief and side effects, which can include irreversible complications such as incontinence and erectile dysfunction,” explained Dr. Abourbih. “Aquablation therapy offers low rates of irreversible complications and long-term relief.”

To learn more about aquablation therapy, visit garnethealth.org/aquablation. If you or someone you know is having prostate issues, call (845) 333-7575 in Orange County or (845) 333-8909 in Sullivan County to make an appointment with a Garnet Health Doctors urologist. 

About Garnet Health 

Garnet Health is a New York State not-for-profit corporation headquartered in Middletown, New York, approximately 60 miles northwest of New York City. It is the corporate parent of Garnet Health Medical Center, Garnet Health Medical Center – Catskills, Garnet Health Doctors, Garnet Health Urgent Care, Garnet Health Foundation and Garnet Health Foundation – Catskills. Garnet Health is dedicated to developing specialty services, medical programs and needed healthcare services that allow residents to remain close to home to receive quality care.

Providing healthcare to approximately 500,000 residents in Orange, Sullivan and Ulster counties, Garnet Health was designed to improve the quality, stability and efficiency of healthcare services in the mid-Hudson and Catskills region. Garnet Health provides the services of more than 4,000 employed professionals and over 850 medical staff members. An academic affiliate of the Touro College of Osteopathic Medicine, Garnet Health retains compassionate professionals who continually strive toward the hospital’s mission to improve the health of our community by providing exceptional healthcare. To learn more about Garnet Health, visit garnethealth.org. 

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam® Robotic System, an advanced, image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS) due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.